Quiet Period Expiration For Minerva Neurosciences IPO: Short-Term Buying Window
- July 25 will conclude the 25 day, SEC-enforced quiet period on underwriter research on NERV.
- On July 26th, NERV's underwriters will likely release detailed positive reports, leading to at least a temporary rise in NERV prices.
- NERV's post-IPO market performance has been inconsistent, bouncing between $5.75 per share and $7.54 per share.
- Given that each of NERV's product candidates is at an early clinical stage, we feel that the firm has an unclear future; however, this event offers a short-term buying opportunity.